Latest News

Update on AUY922 development programme

Vernalis plc today announces that Novartis has informed Vernalis that it is has ceased all development work on AUY922, the novel intravenous Hsp90 inhibitor and rights from the programme will now revert to Vernalis...

Read more...

At a glance

More information on Vernalis and it's pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form